- Home
- MRSN vs IBEX Comparison
MRSN vs IBEX Comparison
Compare MRSN & IBEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- IBEX
- Stock Information
- Founded
- MRSN 2001
- IBEX 2017
- Country
- MRSN United States
- IBEX United States
- Employees
- MRSN N/A
- IBEX N/A
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- IBEX EDP Services
- Sector
- MRSN Health Care
- IBEX Technology
- Exchange
- MRSN Nasdaq
- IBEX Nasdaq
- Market Cap
- MRSN 252.0M
- IBEX 267.7M
- IPO Year
- MRSN 2017
- IBEX 2020
- Fundamental
- Price
- MRSN $0.62
- IBEX $22.13
- Analyst Decision
- MRSN Buy
- IBEX Buy
- Analyst Count
- MRSN 6
- IBEX 4
- Target Price
- MRSN $6.00
- IBEX $21.25
- AVG Volume (30 Days)
- MRSN 7.3M
- IBEX 137.0K
- Earning Date
- MRSN 02-26-2025
- IBEX 02-06-2025
- Dividend Yield
- MRSN N/A
- IBEX N/A
- EPS Growth
- MRSN N/A
- IBEX 10.28
- EPS
- MRSN N/A
- IBEX 1.88
- Revenue
- MRSN $34,837,000.00
- IBEX $513,677,000.00
- Revenue This Year
- MRSN N/A
- IBEX $4.89
- Revenue Next Year
- MRSN N/A
- IBEX $4.31
- P/E Ratio
- MRSN N/A
- IBEX $11.74
- Revenue Growth
- MRSN N/A
- IBEX N/A
- 52 Week Low
- MRSN $0.56
- IBEX $13.00
- 52 Week High
- MRSN $6.28
- IBEX $22.47
- Technical
- Relative Strength Index (RSI)
- MRSN 20.37
- IBEX 64.60
- Support Level
- MRSN $0.56
- IBEX $20.18
- Resistance Level
- MRSN $1.45
- IBEX $21.61
- Average True Range (ATR)
- MRSN 0.14
- IBEX 0.68
- MACD
- MRSN -0.06
- IBEX 0.05
- Stochastic Oscillator
- MRSN 6.49
- IBEX 85.15
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.
About IBEX IBEX Limited
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.